Dr. Dennis Slamon's honor in precision medicine masks the crushing reality of high drug costs and access inequality in modern healthcare.
The WEF's focus on women's health investment isn't just altruism—it's a massive economic pivot. Unpacking the hidden winners and losers in this new frontier of healthcare funding.
New science suggests psychiatric disorders share a root cause. This isn't just a breakthrough; it’s a massive realignment of the mental health industry.
The BHF's massive data science investment isn't just about saving hearts; it's about who owns the future of **cardiovascular health data**.
Lumos AI promises precision in mental health drugs, but who really profits? Unpacking the dark side of AI in psychiatric drug development.
Daisy Genomics just snagged $2.5M for precision medicine. But this small raise masks a brutal truth about early-stage biotech funding and AI integration.
Forget the hype. Deep analysis of CRISPR-based Cellgorithm technology reveals the hidden power struggle and true timeline for this cell programming revolution.
A quiet Frederick company is set to unveil new bio technology. But who *really* stands to gain from this biotech revolution?